company background image
4880 logo

CellSource TSE:4880 Stock Report

Last Price

JP¥1.51k

Market Cap

JP¥29.9b

7D

6.9%

1Y

-35.6%

Updated

23 Jul, 2024

Data

Company Financials +

4880 Stock Overview

Engages in the regenerative medicine-related businesses in Japan.

4880 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth3/6
Past Performance1/6
Financial Health6/6
Dividends0/6

CellSource Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CellSource
Historical stock prices
Current Share PriceJP¥1,510.00
52 Week HighJP¥2,600.00
52 Week LowJP¥1,129.00
Beta0.19
11 Month Change22.66%
3 Month Change-1.05%
1 Year Change-35.61%
33 Year Change-69.23%
5 Year Changen/a
Change since IPO93.59%

Recent News & Updates

Shaky Earnings May Not Tell The Whole Story For CellSource (TSE:4880)

Jun 20
Shaky Earnings May Not Tell The Whole Story For CellSource (TSE:4880)

Recent updates

Shaky Earnings May Not Tell The Whole Story For CellSource (TSE:4880)

Jun 20
Shaky Earnings May Not Tell The Whole Story For CellSource (TSE:4880)

Shareholder Returns

4880JP Life SciencesJP Market
7D6.9%-0.5%-2.3%
1Y-35.6%-35.4%21.0%

Return vs Industry: 4880 matched the JP Life Sciences industry which returned -35.4% over the past year.

Return vs Market: 4880 underperformed the JP Market which returned 21% over the past year.

Price Volatility

Is 4880's price volatile compared to industry and market?
4880 volatility
4880 Average Weekly Movement7.4%
Life Sciences Industry Average Movement5.2%
Market Average Movement3.7%
10% most volatile stocks in JP Market7.3%
10% least volatile stocks in JP Market1.8%

Stable Share Price: 4880 has not had significant price volatility in the past 3 months.

Volatility Over Time: 4880's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of JP stocks.

About the Company

FoundedEmployeesCEOWebsite
2015151Takashi Sawadawww.cellsource.co.jp

CellSource Co., Ltd. engages in the regenerative medicine-related businesses in Japan. The company provides processing services to extract adipose-derived stem cells from patients’ adipose tissues, and to prepare platelet-rich plasma from patients’ blood; and offers support services for medical facilities providing regenerative medicine therapy, as well as manufacturing processed cells. It is also involved in the development and sale of Signalift series of anti-aging products, including a serum.

CellSource Co., Ltd. Fundamentals Summary

How do CellSource's earnings and revenue compare to its market cap?
4880 fundamental statistics
Market capJP¥29.91b
Earnings (TTM)JP¥812.00m
Revenue (TTM)JP¥4.57b

36.8x

P/E Ratio

6.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4880 income statement (TTM)
RevenueJP¥4.57b
Cost of RevenueJP¥1.50b
Gross ProfitJP¥3.07b
Other ExpensesJP¥2.25b
EarningsJP¥812.00m

Last Reported Earnings

Apr 30, 2024

Next Earnings Date

Sep 12, 2024

Earnings per share (EPS)41.00
Gross Margin67.13%
Net Profit Margin17.78%
Debt/Equity Ratio0%

How did 4880 perform over the long term?

See historical performance and comparison

Dividends

0.3%

Current Dividend Yield

n/a

Payout Ratio

Does 4880 pay a reliable dividends?

See 4880 dividend history and benchmarks
When do you need to buy 4880 by to receive an upcoming dividend?
CellSource dividend dates
Ex Dividend DateOct 30 2024
Dividend Pay DateJan 09 2025
Days until Ex dividend98 days
Days until Dividend pay date169 days

Does 4880 pay a reliable dividends?

See 4880 dividend history and benchmarks
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.